Listed by the USPTO as BOESEN, AGNIESZKA
Tech Center 1600 • Art Units: 1632 1648 1652 1671 1672
This examiner grants 69% of resolved cases
BOESEN, AGNIESZKA handles matters in tech center 1600 and art unit 1632. The profile covers 847 resolved cases and reports an allowance rate of 68.6%. The median time to allowance is 1170 days, indicating that applicants should plan for a lengthy prosecution cycle.
Interviews are associated with a 21.8% lift in the allowance rate. This supports treating interview preparation as a potentially useful component of prosecution strategy. The listed companies are Intervet Inc., Eye Vacc, and ModernaTX Inc. The listed firms are Morgan, Lewis & Bockius LLP (WA), NORTON ROSE FULBRIGHT US LLP, and BROWN RUDNICK LLP. The substantial resolved-case volume gives practitioners a broad record for examiner-specific review.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18280362 | VLP ENTEROVIRAL VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18288460 | AAV Capsids and Uses Thereof | Non-Final OA | The General Hospital Corporation |
| 18260110 | HERPES SIMPLEX VIRUS TYPE 1 DERIVED INFLUENZA VACCINE | Non-Final OA | The Regents of the University of California |
| 18830643 | ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18283042 | Highly Attenuated Replication-Competent Recombinant Poxvirus As A Vaccine Platform And Methods Of Use | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18723259 | STABILISED LIQUID VACCINES OF LIVE VIRUSES | Non-Final OA | INTERVET INC. |
| 18702577 | A VACCINE FOR THE PROTECTION OF PIGLETS AGAINST SWINE INFLUENZA A VIRUS INFECTION | Non-Final OA | Intervet Inc. |
| 18750780 | ANTI-CAR COMPOSITIONS AND METHODS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18687763 | IMMUNOFOCUS ASSAY FOR DETERMINING THE TITER OF DENGUE VIRUSES | Non-Final OA | TAKEDA VACCINES, INC. |
| 18667046 | RSV IMMUNIZATION REGIMEN | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.6% of resolved applications examined by Agnieszka Boesen were allowed (847 resolved cases), compared with 38.1% across Art Unit 1632 over the last five years.
This examiner's interview lift is +21.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Agnieszka Boesen took 1,170 days on average from filing to allowance.
Agnieszka Boesen examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
